D-Dimer as Predictor of Disease Outcome in Intensive Care Unit in COVID-19m Patients
NCT ID: NCT05279469
Last Updated: 2022-03-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
465 participants
OBSERVATIONAL
2021-06-10
2022-03-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of Red Cell Distribution Width's Prognostic Ability in Septic Intensive Care Unit Patients
NCT06847451
Non-invasive Predictors of ICU Admission and Mortality in Initially Asymptomatic COVID-19 Patients
NCT05298852
Serum CD14 and CD88 Mointoring in ICU
NCT02120534
PREdiction of DIagnosed Covid-19 infecTion in IUC Patients
NCT04327180
Characteristics of Critically Ill COVID 19 Patients
NCT04465058
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
It has been reported that COVID 19 is associated with hemostatic abnormalities and elevated D-Dimer level, so its level is used to predict severity of disease.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
no intervention, just observational for D-Dimer level in blood
observation for basal D-Dimer and 48 hours later D-Dimer in blood for ICU SARS.COV.2 patients
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* positive PCR
* requiring oxygen therapy
Exclusion Criteria
* negative PCR
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amr M Hilal Abdou
Assistant Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ain shams university hospitals
Cairo, , Egypt
Faculty of medicine, Ain Shams University
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MS56/2022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.